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Dementia and, in particular, Alzheimer’s disease (AD), affects millions of people around the 
world and its prevalence is steadily rising annually. Some risk factors for AD, such as age, can-
not be modified, while others could possibly be corrected. In recent years, many studies are 
tackling the problem of the oral and gut microbiota as a provoking factor for AD and other 
neurodegenerative diseases, but their relationship and specific pathophysiological mecha-
nisms remain understudied. The microbiota of the oral cavity can be of particular importance 
due to the specificity of microorganisms and their localization, as well as the possibility of 
provoking neuroinflammation, which requires further study. This review covers the specific 
features of the oral microbiota, current views on the pathophysiological role of the oral micro-
biota in the development of AD, as well as the beneficial role of probiotics. The study of this 
issue can have an important practical application both for the early diagnosis of AD, and for 
its further treatment.
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Introduction
Age-associated diseases are becoming more and more urgent problem, significantly 
reducing the quality and duration of life of the elderly. Being the most common cause of 
dementia in developed countries, Alzheimer’s disease (AD) is becoming more and more 
widespread nosology. Nowadays, oral bacteria, their structural components and metabo-
lites have been considered as one of the prominent risk factors for AD. The deposition of 
beta-amyloid, which is one of the key components in the AD development, occurs long 
before the clinical manifestation of the disease and, according to recent data, can be trig-
gered by several risk factors, including microbiota. Understanding the role of the oral cav-
ity bacteria, their components and metabolites in the pathogenesis of AD may contribute 
to the early diagnosis of dementia, as well as the development of new approaches to the 
management of elderly and senile patients with cognitive impairment.
Aim of the study: to investigate the possible pathogenic role of the oral bacteria in 
the development of Alzheimer’s disease, which can be applied to develop therapeutic 
strategies for preventing and slowing the progression of this disease.
Features of the microbial composition of the oral cavity
The oral cavity (OC) in humans includes the lips, the cheeks, the hard and soft palate, 
as well as the muscular diaphragm that makes up its bottom. The OC also includes the 
alveolar ridges, the gums, the teeth, the tongue, the palatine and the lingual tonsils. Differ-
ent areas of the OC differ in their anatomical, physiological and physicochemical proper-
ties, which leads to a non-uniform distribution of microorganisms [1]. One milliliter of 
saliva contains approximately 108 microbial cells [2]. Several studies have identified up to 
700 different taxa of prokaryotes in saliva [3], while a typical healthy microbiome consists 
of approximately 100-200 different bacterial species [4].
The microbiota of the OC is mostly presented with such genera as Streptococcus, Ac-
tinomyces, Veillonella, Granulicatella, Gemella, Corynebacterium, Rothia, Fusobacterium, 
Porphyromonas, Prevotella, Capnocytophaga, Neisseria, Haemophilus, Treponema, Lacto-
bacteria. The OC has a number of well-defined “niches” formed on various surfaces in the 
mouth. According to numerous studies, the microbiomes of each area of  the OC (tongue, 
gums, palate, subgingival and supragingival plaque, etc.) have a general similarity, but at 
the same time, they have their own ratio of the abovementioned bacterial genera [5; 6]. 
For example, the subgingival region is inhabited mainly by anaerobes of the genus Actino-
myces and Fusobacterium nucleatum [7; 8], on the back of the tongue mainly Streptococ-
cus salivarius, Rothia mucilaginosa, and various species of the genus Eubacterium [9] are 
described, in saliva and in the mucous membrane of the cheeks, higher concentrations of 
microorganisms such as Firmicutes are found [10; 11]. The composition of the MB is also 
different when considering the “cross section” of the microbial film. Closer to the enamel 
surface, an increased number of bacteria of the genus Actinomyces is observed in dental 
plaque, and the radially located bacteria of the genus Corynebacterium structure the bio-
film, creating a habitat for other organisms [6].
In addition, individual differences are observed in the composition of MB of the OC, 
due to the environment, genetic characteristics, age and lifestyle of a particular person. 
Changes in the availability of oxygen, nutrients and the pH-mediated effect of saliva can 
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promote the growth of various organisms [12], and conversely, these organisms can par-
ticipate in the construction of their own small niche [13] through the formation of bio-
films and nutrients. However, due to such property of the MB as “functional redundancy”, 
individual characteristics do not significantly affect its normal functioning.
However, when the ability of the MB as an ecosystem to resist and recover is im-
paired, there is a pathological change in its composition with the development of inflam-
matory diseases of the OC, associated partly with the presence of oral cavity infections, 
partly with the formation of a systemic inflammatory response observed in a number of 
somatic diseases [14–16]. At the same time, OC communicates with the respiratory and 
digestive systems and has a rich blood supply, which suggests the potential participation 
of oral MB in the development of other systemic diseases. An increasing number of stud-
ies demonstrate the connection between internal organ diseases and changes in the MB of 
the OC. This, in turn, suggests that a change in the composition of the latter can serve as 
a potential biomarker in the diagnosis of some systemic diseases.
Role of the oral microbiota in the development of Alzheimer’s disease
The results of recent studies have demonstrated the relationship of inflammatory dis-
eases of the OC with the development and progression of AD [17–19]. In particular, a 
number of clinical and experimental studies have revealed a relationship between peri-
odontitis and a progressive decline in cognitive functions in AD [20]. On the one hand, 
patients with dementia have difficulties in maintaining oral hygiene and impaired oral 
motility, which is a risk factor contributing to the development of inflammatory diseases. 
On the other hand, it cannot be denied that some features of the microbial composition of 
the oral cavity can provoke the development and progression of AD [14].
The most studied pathogenic bacteria of the oral cavity associated with AD are P. gin-
givalis, T. denticola, T. forsythia, T. socranskii, A. actinomycetemcomitans, C. rectus, F. nu-
cleatum, E nodatum, A. naeslundii, and C. pneumonia [15]. P. gingivalis DNA was found 
during autopsy of the brain of AD patients [16], while Borrelia burgdorferi was the first 
microorganism isolated from the blood and cerebrospinal fluid of AD patients [17]. An-
other bacterium often found in the brain tissue and cerebrospinal fluid of patients with 
AD is Treponema denticola, which can move both through the systemic blood flow and 
along the neuronal pathways. The latter assumption is supported by the fact that in a 
number of patients this microorganism was isolated from the trigeminal ganglia [18; 19].
AD is believed to be largely associated with neuroinflammation, which can be en-
hanced by systemic inflammation. According to the recent data, inflammatory diseases 
of the OC, being a chronic peripheral infection, cause a significant systemic inflamma-
tory response. In addition, it is assumed that oral MB can influence the development of 
AD due to the invasion of microorganisms into the brain tissue and stimulation of the 
local immune response [21]. Presumably, the penetration of the OC bacteria into the cen-
tral nervous system is performed via the bloodstream, followed by penetration through 
the blood-brain barrier (BBB), which may become more permeable with age. The other 
possibilities include involvement of the perivascular spaces, as well as the olfactory and 
trigeminal nerves [21; 22].
Unique neuropathological features of AD include extracellular accumulation of beta-
amyloid (βA) peptide and intracellular accumulation of hyperphosphorylated tau protein 
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[23; 24]. Using the example of intestinal MB, it has been demonstrated that bacteria in-
habiting the intestine can secrete significant amounts of amyloid and lipopolysaccharides, 
which can play a role in modulating signaling pathways and the production of proinflam-
matory cytokines associated with the pathogenesis of AD [25].
It is assumed that when the composition of oral MB is disrupted, the emerging inva-
sion of microorganisms into the brain tissue leads to the disruption of calcium transport 
in neurons, causes neuroinflammation, and contributes to the accumulation of βA due to 
the deposition of its own amyloid peptides and stimulation of βA production by the glial 
cells [26]. For example, in vitro Borrelia burgdorferi stimulates glial and neuronal cells to 
synthesize βA and tau protein [17].
However, as shown by the study by Laugisch et al., although the entry of bacterial 
components into the brain through the systemic circulation is an important mechanism 
in the progression of AD, it is still not a triggering factor [22]. Nevertheless, from the 
point of view of the amyloid hypothesis that the accumulation of βA is the reason for the 
development of AD, bacteria and pathogens that trigger or increase the production of this 
substance may serve as the primary cause of the progression of the disease.
Currently, lipopolysaccharide (LPS) are considered to play one of the main roles in 
the development of a number of neurodegenerative diseases, including AD. Zhan et al. 
demonstrated that the administration of LPS obtained from gram-negative bacteria, fol-
lowed by ischemia-hypoxia, leads to the formation of plaque-like aggregates of β-amyloid 
in the rat brain (β-A) [27].
It is believed that the influence of LPS on the development of AD is realized through 
several mechanisms [28–30]. As potential endotoxin, LPS activates toll-like receptors 4 
(TLR4) of endothelial cells, triggering the nuclear factor kappa-light-chain-enhancer of 
activated B cells (NFkB) transcription factor, which leads to the assembly the NLRP3 
(NOD-, LRR- and pyrin domain-containing protein-3)  inflammasome, which mediates 
the synthesis of the pro-inflammatory cytokine IL-1β (interleukin-1β) [31]. Research by 
Dempsey et al. showed that inhibition of NLRP3 significantly reduces β-A levels and im-
proves cognitive function in patients with AD [32].
Besides, by disrupting the structure of myelin, LPS can increase the level of degraded 
myelin basic protein (dMBA). This protein is described in amyloid plaques in a complex 
with β-A. It is assumed that it promotes the formation of amyloid plaques. LPS can also 
act on the blood-brain barrier (BBB), inhibit the apolipoprotein E receptor, decreasing the 
clearance of β-A, and thereby contribute to its accumulation. LPS has also been shown to 
induce hyperphosphorylation of the tau protein.
In addition to LPS, other bacterial toxins may play a role in the development of AD. 
For example, P.  gingivalis synthesizes toxic proteases called gingipain, which have also 
been found in brain tissue, cerebrospinal fluid, and saliva in AD patients, and high levels 
of which are correlated with tau protein and ubiquitin levels. A possible mechanism of 
action of these proteases is a damaging of the tight junctions of endothelial cells, which 
may increase the BBB permeability for bacteria and inflammatory mediators. It has been 
shown, that oral administration of low molecular weight inhibitors gingipain (COR388) 
reduces β-A production and neuroinflammation [33].
Some bacteria are able to synthesize special proteins of the outer membrane — por-
ins. F. nucleatum produces porin FomA (major outer membrane protein A), T. pallidum 
expresses the TprC/D and TprI proteins with porin-like activity, T.  denticola contains 
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a surface antigen (Msp), which demonstrates the activity of adhesin and porin. It has been 
shown that porins can move from bacteria to cell membranes, causing damage and, as a 
result, ionic imbalance. Thus, bacterial porins, disrupting the permeability of nerve cell 
membranes, can contribute to β-A “leakage”, its circulation, accumulation and toxic ef-
fects. In addition, porins can cause excess calcium intake into cells, contributing to their 
death [34]. 
Possible role of probiotics in correcting Alzheimer’s disease
The above-described probable relationship of human MB with the development of 
AD opens the question of the possible use of probiotics in the prevention and therapy 
of neurodegenerative processes. Probiotics are viable microorganisms that, when used 
in adequate amounts, are capable of exerting a therapeutic effect on various pathological 
processes. Their influence on the qualitative and quantitative composition of the micro-
biota is performed through both direct and indirect effects [35]. So probiotics are able to 
influence MBs, inhibiting the growth of pathogenic microorganisms by developing their 
own antimicrobial compounds, competition for nutrients and sites of attachment to host 
tissues. For example, in patients with chronic periodontitis, prescribing probiotics with 
Lactobacillus reuteri show a decrease in the number of P. gingivalis in saliva [36], as well 
as a decrease in the concentration of A. actinomycetemcomitans, P. gingivalis, and P. iner-
media in the supragingival plaque [37]. In addition, probiotic bacteria are able to alter the 
production of cytokines and thereby influence the general and local immune response 
[38]. Szkaradkiewicz et al. has been shown that the use of a probiotic with L. reuteri in ad-
dition to conventional treatment leads to a decrease in inflammatory cytokines, including 
TNF-alpha, IL-1 beta and IL-17 [39].
The bacteria that are part of many probiotics and have a beneficial effect on the prog-
nosis in AD include Bifidobacterium spp., which reduce the manifestations of the inflam-
matory process and the concentration of pro-inflammatory cytokines [40]. It has been 
demonstrated in vitro that certain types of lactobacilli and bifidobacteria produce neu-
rotransmitters such as gamma-aminobutyric acid (GABA) and acetylcholine, which may 
have a beneficial effect on cognitive and behavioral aspects [41].
Bonfili et al. in their 2017 study on laboratory animals of the 3xTg-AD line, predis-
posed to the development of AD, showed that the use of the probiotic SLAB51, which 
affects the composition of the intestinal MB and its metabolites, significantly reduces 
cognitive deficit in the animals under study by slowing down the processes of neurode-
generation. According to the authors, the improvement of cognitive processes occurred 
due to the partial restoration of two impaired neuronal proteolytic pathways  — the 
ubiquitin proteasome system and autophagy [40]. Abraham et al. demonstrated on ani-
mal models that treatment with probiotics in combination with exercise can slow down 
the progression of AD, which can presumably be mediated by changes in the micro- 
biome [42].
In the study of oral administration of the strain A1 Bifidobacterium breve (B. breve 
A1) on behavior and physiological processes in AD mice, a partial reduction in the cog-
nitive deficit observed in AD mice was also noted. In addition, consumption of B. breve 
A1 suppressed the expression in the hippocampus of inflammation and immunoreactive 
genes, which are induced by β-amyloid [43].
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Separate studies of the effect of probiotic supplementation on cognitive function and 
metabolic status in people with AD have shown a significant improvement in mental state 
and a positive effect of probiotics on some metabolic parameters, such as, for example, 
C-reactive protein, insulin resistance, triglycerides, inulin sensitivity index [44].
It should be noted that most of the studies on the effect of probiotic therapy on the de-
velopment of AD concerned the investigation of the intestinal microbiota. To date, there 
is a small number of the published data confirming the improvement in the condition 
of patients with asthma during therapy with probiotics for their existing inflammatory 
disease of the oral cavity. Nevertheless, based on the possible role of the oral microbiota 
in the progression of neurodegenerative diseases, it is assumed that oral probiotics may 
play a positive role in the prevention and correction of cognitive impairment in elderly 
patients, which requires further research.
Conclusion
Alzheimer’s disease is a neurodegenerative disease, where various pathophysiologi-
cal aspects are still remaining understudied. A sufficient amount of data suggests a pos-
sible relationship between the gut and oral microbiota and the development of AD. Fur-
ther study of the features of the oral MB in patients with AD may contribute to the 
development of methods for the early diagnosis of the disease based on the identification 
of certain types of bacteria in the oral cavity and their structural components associated 
with AD.
The data accumulated to date on the possible relationship between AD and MB, the 
effect of MB on brain activity and its ability to cause brain dysfunction, open up prospects 
for the search for new methods of prevention and therapeutic action using pro/prebiotics. 
The results of in vitro studies, in animal models, as well as a few studies among patients 
with AD indicate a beneficial effect of the use of probiotics on the cognitive and behavioral 
aspects of AD. Studies of the oral cavity microbiota as a therapeutic target in the treatment 
of neurodegenerative diseases, including AD has great interest and prospects for further 
development. The probiotics administration on the microbiome of the gastrointestinal 
tract, including the oral cavity, may improve the quality of life of patients and slow down 
the AD progression.
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